Sign in
Taking peoplePhase 2/3

Effect of Probiotics "Psychobiotics" on Depression and Metabolic Syndrome in Saudi Arabia

Key facts

Who runs it
Roaa Ahmed Alkreadees
Where
Saudi Arabia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
60 people, planned
Started
2 Mar 2025
Expected to end
30 Jan 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Winclove's Ecologic® Barrier Probiotics
  • Winclove's Ecologic® Barrier Probiotics Placebo
Record updated
22 September 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Major Depression Disorder (MDD) patients on antidepressants for at least 4 weeks or more
  • MDD patients with pre-metabolic syndrome (at least 2 of the MetS components) and metabolic syndrome (at least 3 of the following components: central obesity with WC for men ≥ 94 centimeters while for women ≥ 80 centimeter, increased FPG ≥ 100 mg/dl, increased BP to ≥ 130 / ≥ 85 mmHg, increased TGs equal or above 150 mg / dl, increased HDL cholesterol for men to < 40 mg / dl while for women < 50 mg / dl) (IDF., 2006)
  • MDD patients with other comorbid diseases such as anxiety

Who cannot take part

  • Patients using pre/pro/symbiotics supplement or antibiotics during the last 3 weeks before the intervention
  • Patients with modified antidepressant dose during interventional period or receiving psychotherapy during the intervention
  • patients receiving injections or medications to lose weight (Ozempic, Mounjaro …etc) either 3 weeks before or during the intervention
  • Patients using plasma-lipid lowering drug for less than 1 month before the intervention
  • Patients with chronic diseases (cardiac, renal, or hepatic diseases)
  • Patients with gastro intestinal diseases (Crohn's disease, ulcerative colitis)
  • Patients with infectious diseases (HIV/AIDS)
  • Cancer patients or those undergoing chemotherapy
  • Patients with food allergies such as gluten intolerance or lactose intolerance
  • Patients with thyroid disorder
  • Patients using any other supplements to improve mood
  • Pregnant and breastfeeding women
  • Patients following a diet to lose weight during the intervention
  • Diabetic patients who are insulin-dependent
  • Patients with substance abuse including alcohol addiction

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial is currently available in Saudi Arabia.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to assess the effect of commercial multi-strains psychobiotics supplementation as an ad-on therapy on depressive symptoms and metabolic syndrome components (HDL-C, FPG, TGs, WC, BP) in adult depressed patients with pre-metabolic syndrome and metabolic syndrome. The second goal is to explore the effect of commercial multi-strains psychobiotics supplementation on the anthropometric measurement (weight, body mass index (BMI)) in adult depressed patients with pre-metabolic syndrome and metabolic syndrome. The main questions they aim to answer are:

Read full original descriptionShow less

* Will commercial multi-strains psychobiotics supplementation help to ease depressive symptoms as an ad-on therapy in patients with pre-metabolic syndrome and metabolic syndrome? * Will commercial multi-strains psychobiotics supplementation improve anthropometric measurements and metabolic syndrome components (WC, FPG, BP, TGs, HDL-C) in depressed patients? Researchers will compare psychobiotics to a placebo (a look-alike substance that contains no drug) to see if psychobiotics work to improve depression and metabolic syndrome components.

Participants will:

* Be examined for depression, anxiety, and metabolic syndrome components (waist circumference, diabetes, blood pressure, triglycerides, and high-density lipoprotein). * Be asked to conduct laboratory tests to determine the inclusion and exclusion criteria. * Be given probiotics/ placebo to consume every day for 3 months (12 weeks). * Repeat the examination and laboratory tests to determine the results. * Be followed up weekly for adverse events and to insure their compliance with the study instructions. * Be followed up after 4 weeks as an end-visit and will conduct the examination and the laboratory blood tests.

The 2 groups in the trial

  • Winclove's Ecologic® Barrier ProbioticsTreatment being tested

    Patients in the interventional group will consume psychobiotics daily in addition to their antidepressant medication for 12 weeks. All patients will be instructed to take 1 sachet in the morning before breakfast, and 1 sachet at the end of the day before going to bed. The product is a multispecies probiotic formulation consisting of 9 selected probiotic strains by Winclove's Ecologic® Barrier, Amsterdam, The Netherlands. Each participant will receive 6 boxes of the probiotic supplement, each box contains 30 sachets of 3 grams (180 sachets in total). During the period of 12 weeks, each participant will consume 168 sachets. The probiotic supplement is a freeze-dried powder of probiotic mixture at a dose of 2,5 x 109 colony forming units (CFU) per gram. Since participants should consume 2 sachets/day, they will consume 6 grams in total which equals 1.5 × 10\^10 CFU.

  • ControlPlacebo, for comparison

    Patients in the control group will consume similar sachets that are identical in physical appearance. The placebo is composed of the carrier of the probiotic product, that is maize starch and maltodextrins but contains no bacteria.

    Treatment: Winclove's Ecologic® Barrier Probiotics Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Probiotics "Psychobiotics" on Depression in Adults With Pre-Metabolic Syndrome and Metabolic Syndrome in Riyadh City
Criteria questions
Built from NCT06765057, who can take part
Record updated
22 September 2025